Clinical Trial Update: Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease

View source ↗

Summary

This clinical trial update reports on the long-term outcomes after interruption of vemurafenib, a BRAF inhibitor, in patients with Erdheim-Chester disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erdheim-chester Disease

Drugs mentioned

• Vemurafenib (Zelboraf) (vemurafenib)

Snippet

Sponsor: Groupe Hospitalier Pitie-Salpetriere | Conditions: Erdheim-Chester Disease | Status: UNKNOWN